Bone Density Conservation Agents/administration & dosage/economics; Budgets; Calcitriol/administration & dosage/economics; Costs and Cost Analysis; Drug Costs; Ecuador; Ergocalciferols/administration & dosage/economics; Female; Hospitalization/economics; Humans; Hyperparathyroidism, Secondary/drug therapy/economics; Kidney Failure, Chronic; Male; Medical Audit; Middle Aged; Quality of Life; Renal Dialysis; Retrospective Studies; Calcitriol; Paricalcitol; Renal kidney disease
Abstract :
[en] BACKGROUND: Chronic kidney disease (CKD) is a disorder with high morbidity and mortality worldwide whose complications generate multiple costs. In Ecuador, only a few healthcare institutions have implemented management protocols aimed to reduce costs and to improve the quality of life of patients. The aim of this study is to evaluate the short-term (1-year) and long-term (5-year) costs and savings in the management of secondary hyperparathyroidism (SHPT) of hemodialyzed CKD patients by comparing calcitriol and paricalcitol in a large social security hospital in Quito, Ecuador. METHODS: The estimation model assessed the resources used in the management of SHPT by comparing prospectively the cost savings within 1-year and 5-year time horizon with calcitriol and paricalcitol. Hospitalization, erythropoietin (EPO), treatment doses, intravenous iron consumption, and medical supplies were estimated according international references, based on the initial parathormone level (iPTH) of patients. The Ecuadorian National Reference costs (2014-2015) and institutional costs were used to calculate treatment costs. A statistical sensitivity analysis was also performed. RESULTS: The study was based on data from 354 patients of whom 147 (41.4 %) had a value of iPTH in the range 300-600 pg/ml, 45 (12.8 %) in the range 601-800 pg/ml, and 162 (45.7 %) over 800 pg/ml. The 1-year estimated costs per patient for calcitriol and paricalcitol, respectively, were: medication, 63.88 USD and 1,123.44 USD; EPO, 19,522.95 USD and 16,478 USD; intravenous iron 143.21 USD and 187.76 USD. Yearly hospitalization costs per patient were 11,647.99 USD with calcitriol and 8,019.41 USD with paricalcitol. Total yearly costs per patient amounted to 31,378.02 USD with calcitriol and 25,809.50 USD with paricalcitol. Total savings using paricalcitol were 5,568.52 USD per patient compared with calcitriol. The 5-year cumulative medication costs were 319 USD for calcitriol and 2,403 USD for paricalcitol; EPO with calcitriol was 97,615 USD and with paricalcitol 82,394 USD; intravenous iron with calcitriol was 716 USD and paricalcitol 939 USD. Hospitalization costs for patients with calcitriol and paricalcitol were 43,095 USD and 62,595 USD, respectively. Total savings using paricalcitol amounted 32,414 USD per patient compared with calcitriol. CONCLUSIONS: Paricalcitol use generated more cost savings than calcitriol after 1 and 5 years.
Disciplines :
Urology & nephrology
Author, co-author :
Manjarres, Luis
Sanchez, Pilar
Cabezas, Maria C.; Pontifical Catholic University of Ecuador, Ecuador > Medical School
Fornasini, Marco
Freire, Valeria
Albert, Adelin ; Université de Liège - ULiège > Département des sciences de la santé publique > Département des sciences de la santé publique
Language :
English
Title :
Budget impact of secondary hyperparathyroidism treatment in chronic kidney disease in an Ecuadorian social security hospital.
Braun L, Sood V, Hogue S, Lieberman B, Copley-Merriman C. High burden and unmet patient needs in chronic kidney disease. Int J Nephrol Renovasc Dis. 2012;5:151-63.
Stengel B, Combe C, Jacquelinet C, Briancon S, Fouque D, Laville M, Frimat L, Pascal C, Herpe YE, Deleuze JF, et al. The French Chronic Kidney Disease-Renal Epidemiology and Information Network (CKD-REIN) cohort study. Nephrol Dial Transplant. 2014;29(8):1500-7.
Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, Saran R, Wang AY, Yang CW. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382(9888):260-72.
Cusumano AM, Gonzalez Bedat MC. Chronic kidney disease in Latin America: time to improve screening and detection. Clin J Am Soc Nephrol. 2008;3(2):594-600.
Singh AK, Farag YM, Mittal BV, Subramanian KK, Reddy SR, Acharya VN, Almeida AF, Channakeshavamurthy A, Ballal HS PG, et al. Epidemiology and risk factors of chronic kidney disease in India-results from the SEEK (Screening and Early Evaluation of Kidney Disease) study. BMC Nephrol. 2013;14:114.
Thomas R, Kanso A, Sedor JR. Chronic kidney disease and its complications. Prim Care. 2008;35(2):329-44. vii.
Drueke TB, Eckardt KU. Role of secondary hyperparathyroidism in erythropoietin resistance of chronic renal failure patients. Nephrol Dial Transplant. 2002;17 Suppl 5:28-31.
Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208-18.
Joy MS, Karagiannis PC, Peyerl FW. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. J Manag Care Pharm. 2007;13(5):397-411.
Ramirez J. PREVALENCIA DE HIPERPARATIROIDISMO SECUNDARIO EN PACIENTES SOMETIDOS A HEMODIÁLISIS" CENTRO DE DIALISIS "DR. CARLOS ELIZALDE MONTEVERDE". Guayaquil: UNIVERSIDAD DE GUAYAQUIL; 2010.
Tapia M. EFECTOS COLATERALES POR LA DISMINUCIÓN DEL CALCIO EN PACIENTES CON INSUFICIENCIA RENAL CRÓNICA ATENDIDOS EN LA UNIDAD RENAL CONTIGO DE LA CIUDAD DE LATACUNGA EN EL PERIODO OCTUBRE 2011-FEBRERO 2012. Ambato: Universidad Técnica de Ambato; 2012.
St Peter WL, Khan SS, Ebben JP, Pereira BJ, Collins AJ. Chronic kidney disease: the distribution of health care dollars. Kidney Int. 2004;66(1):313-21.
Kerr M, Bray B, Medcalf J, O'Donoghue DJ, Matthews B. Estimating the financial cost of chronic kidney disease to the NHS in England. Nephrol Dial Transplant. 2012;27(3):iii73-80.
Zhang QL, Rothenbacher D. Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Public Health. 2008;8:117.
Rodriguez-Iturbe B, Bellorin-Font E. End-stage renal disease prevention strategies in Latin America. Kidney Int Suppl. 2005;98:S30-36.
Foley RN, Collins AJ. End-stage renal disease in the United States: an update from the United States Renal Data System. J Am Soc Nephrol. 2007;18(10):2644-8.
Pecoits-Filho R, Campos C, Cerdas-Calderon M, Fortes P, Jarpa C, Just P, Luconi P, Lugon JR, Pacheco A, Paniagua R, et al. Policies and health care financing issues for dialysis in Latin America: extracts from the roundtable discussion on the economics of dialysis and chronic kidney disease. Perit Dial Int. 2009;29 Suppl 2:S222-226.
Bolasco P. Treatment options of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease stages 3 and 4: an historic review. Clin Cases Miner Bone Metab. 2009;6(3):210-9.
Ministerio de Salud y Protección Social. In: Social SIdIdlP, editor. SISPRO Aplicativos Misionales. Colombia: Ministerio de Salud y Protección Social; 2016.
Ecuador GNdlRd. Sistema Oficial de Contratación Pública. Ecuador: Ecuador GNdlRd; 2016.
Naves-Diaz M, Passlick-Deetjen J, Guinsburg A, Marelli C, Fernandez-Martin JL, Rodriguez-Puyol D, Cannata-Andia JB. Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study. Nephrol Dial Transplant. 2011;26(6):1938-47.
Llach F, Yudd M. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. Am J Kidney Dis. 2001;38(5 Suppl 5):S45-50.
National Kidney F. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 Suppl 3):S1-201.
Capuano A, Serio V, Pota A, Memoli B, Andreucci VE. Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients. J Nephrol. 2009;22(1):59-68.
Dobrez DG, Mathes A, Amdahl M, Marx SE, Melnick JZ, Sprague SM. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. Nephrol Dial Transplant. 2004;19(5):1174-81.
Nuijten M, Andress DL, Marx SE, Sterz R. Chronic kidney disease Markov model comparing paricalcitol to calcitriol for secondary hyperparathyroidism: a US perspective. Curr Med Res Opin. 2009;25(5):1221-34.
Lorenzoni V, Pierotti F, Turchetti G. A Budget Impact Analysis (Bia) Of The Use Of Paricalcitol For The Treatment Of Secondary Hyperparathyroidism (Shpt) In End Stage Renal Disease Patients. Value Health. 2014;17(7):A467.
Sanchez-Casillas JL, Ramirez-Lopez-De-N MG. Long-Term Cost Comparison Between Paricalcitol and Calcitriol for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease in Mexico. Value Health. 2013;16(7):A688.
Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 2003;63(4):1483-90.
Cheng S, Coyne D. Oral paricalcitol for the treatment of secondary hyperparathyroidism in chronic kidney disease. Ther Clin Risk Manag. 2006;2(3):297-301.
Rosery H, Bergemann R, Marx SE, Boehnke A, Melnick J, Sterz R, Williams L. Health-economic comparison of paricalcitol, calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism during haemodialysis. Clin Drug Investig. 2006;26(11):629-38.
Riccio E, Sabbatini M, Bruzzese D, Capuano I, Migliaccio S, Andreucci M, Pisani A. Effect of paricalcitol vs calcitriol on hemoglobin levels in chronic kidney disease patients: a randomized trial. PLoS One. 2015;10(3), e0118174.
Afsar B, Agca E, Turk S. Comparison of erythropoietin resistance in hemodialysis patients using calcitriol, cinacalcet, or paricalcitol. J Clin Pharmacol. 2015;55(11):1280-5.
